Extra-virgin olive oil consumption improves the capacity of HDL to mediate cholesterol efflux and increases ABCA1 and ABCG1 expression in human macrophages

Olfa Helal¹, Hicham Berrougui¹, Soumaya Loued¹ and Abdelouahed Khalil¹,²*
¹Research Center on Aging, 1036 rue Belvédère Sud, Sherbrooke, QC, Canada J1H 4C4
²Department of Medicine, Geriatrics Service, Faculty of Medicine, University of Sherbrooke, Sherbrooke, QC, Canada

(Submitted 30 March 2012 – Final revision received 26 July 2012 – Accepted 31 July 2012 – First published online 10 October 2012)

Abstract
The present study was aimed to investigate the effect of 12 weeks of extra-virgin olive oil (EVOO) consumption on the capacity of HDL to promote cholesterol efflux (CE) and to determine which CE pathways are modulated by EVOO consumption. Whole HDL and HDL₂/HDL₃ subclasses were isolated from the plasma of twenty-six healthy volunteers before and after 12 weeks of EVOO consumption (25 ml/d). EVOO consumption increased the capacity of serum and HDL to mediate CE from THP-1, J774 macrophages and Fu5AH cells by 9·8–24·57 %, depending on the cell type. The increase in CE was independent of both HDL concentration and subclass distribution. The three HDL-mediated CE pathways (ATP-binding cassette (ABC) A1, ABCG1 and scavenger receptor class B type I (SR-BI)) were modulated by EVOO consumption. The fluidity of the phospholipidic layer of HDL increased by 13 % ($P < 0·001$) following EVOO consumption compared with baseline. EVOO consumption also increased the release of excess cholesterol from human monocyte-derived macrophages (HMDM) by 44 % ($P < 0·001$), and $ABCA1$ and $ABCG1$ mRNA transcription by 16·08 % ($P < 0·001$) and 35·79 % ($P < 0·01$), respectively. The protein expression of these two cholesterol transporters also increased after EVOO consumption. In contrast, SR-BI mRNA and protein expression in HMDM were significantly lower after 12 weeks of EVOO consumption. Incubating J774 macrophages with EVOO polyphenol extracts induced a concentration-dependent up-regulation of $ABCA1$ and $ABCG1$ expression in macrophages. After 12 weeks of EVOO consumption, the capacity of HDL to mediate CE was improved and the ability of HMDM to release excess cholesterol was enhanced by increasing the expression of ABCA1 and ABCG1 transporters.

Key words: HDL; Extra-virgin olive oil; Cholesterol efflux; ABCA1/ABCG1

The concentration of HDL is inversely associated with the incidence of CHD. HDL are thus considered anti-atherogenic lipoproteins(¹,²). One of the major anti-atherogenic activities of HDL is the regulation of cholesterol homeostasis through the reverse cholesterol transport (RCT) process. RCT involves the transport of excess cholesterol from peripheral tissues back to the liver for elimination in the bile and faeces. The initial step in RCT is thought to be the transfer of cholesterol from cell membranes to acceptor particles and then to apoA-I and HDL(³–⁵). HDL-mediated cholesterol efflux (CE) is the natural rate-limiting step of RCT(⁶) and occurs via three pathways. The first is aqueous diffusion by which free cholesterol molecules spontaneously desorb from the plasma membrane, diffuse through the aqueous phase and become adsorbed on acceptor particles by collision(⁷). The second involves scavenger receptor class B type I (SR-BI)-mediated bidirectional free cholesterol exchanges that depend on the cholesterol gradient. This pathway mediates CE to a wide variety of cholesterol acceptors(⁸). The third involves the ATP-binding cassette receptors ABCA1 and ABCG1, which mediate CE in a unidirectional manner to lipid-poor apoA-I and to other subfamily members of HDL, respectively(⁹–¹¹). The capacity of HDL to mediate CE depends on their biophysical structure and biochemical composition. For example, phosphatidylcholine-enriched HDL increases CE, whereas sphingomyelin-enriched HDL decreases cholesterol influx to macrophages(¹²).

A large body of literature has indicated that diet is one of the most important modifiable determinants of the risk of developing CVD(¹³,¹⁴). Replacement of dietary SFA with higher...
intakes of MUFA from vegetable oils has been reported to be inversely associated with the risk of CHD\(^{15}\).

Olive oil is the main source of fat in Mediterranean regions. The alleged beneficial effects of extra-virgin olive oil (EVOO) have been linked to both its MUFA (mainly oleic acid) and its antioxidant components (e.g. hydroxytyrosol and oleuropein). Olive oil phenolics exert their antioxidant effect both \textit{in vitro} and \textit{in vivo} and have potential cardioprotective activities (reviewed in Visioli et al.\(^{16}\)). Considerable attention is being paid to the potential health benefits of olive oil. Human consumption of olive oil decreases the major risk factors associated with atherosclerosis by improving the lipoprotein profile, blood pressure, oxidative stress and thrombotic profiles (reviewed in Lopez-Miranda et al.\(^{17}\)). Olive oil supplementation also protects against LDL and HDL oxidation\(^{18–20}\) and reduces total cholesterol and LDL-cholesterol levels\(^{21}\). Several studies have investigated the effect of olive oil consumption on plasma HDL levels and have led to controversial results\(^{22–25}\). However, no studies have investigated the effect of olive oil consumption on the functionality of HDL and, particularly, on their capacity to mediate CE. However, it is becoming increasingly apparent that the anti-atherogenic effects of HDL not only depend on their concentration and cholesterol content in the circulatory system, but also, and more importantly, on their biological functionalities\(^{20}\). Furthermore, studies have reported that diet, such as supplementation with MUFA in human subjects, influences lipoprotein functionality by enhancing HDL-mediated CE\(^{27,28}\) and that EVOO consumption increases the phenolic compound content of LDL and HDL, which prevents lipid peroxidation and promotes the anti-atherogenic effect of HDL\(^{20}\).

The goals of the present study were to investigate the effect of 12 weeks of EVOO consumption on the capacity of HDL to promote CE and to determine which CE pathways are modulated by EVOO consumption.

Materials and methods

\textbf{Chemicals}

SDS, EDTA and bovine serum albumin were from Sigma. Dialysis membranes were from Spectrum Medical Industries, Inc. Dulbecco's modified Eagle's medium (DMEM) and fetal bovine serum (FBS) were from Wisent, Inc. All other chemicals were from Sigma-Aldrich. THP-1 cells and J774 macrophages were from the American Type Culture Collection. Fu5AH rat hepatoma cells were provided by Dr J. Genest (McGill University). Roswell Park Memorial Institute (RPMI) 1640 medium was from Invitrogen Canada, Inc. EVOO was from Atlas Olive Oil sarl.

\textbf{Subjects}

A total of twenty-six healthy volunteers aged between 25 and 83 years (eight men and eighteen women, mean age 53.28 (SD 20.66) years) were recruited. They were all non-smokers with a normal serum lipid profile and blood pressure and were not taking medication, including lipid-lowering drugs or oral antioxidants. Both pre- and postmenopausal women were included in the study. However, none of the women was taking oestrogen replacement therapy for menopause. They were all non-obese and none showed clinical signs of inflammation or diabetes. The clinical and biochemical parameters of the volunteers are presented in Table 1.

The present study was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures involving human subjects/patients were approved by the Ethics Committee of the University Institute of Geriatrics of Sherbrooke (no. 2009/19). Written informed consent was obtained from all subjects.

\textbf{Study design and procedure}

The volunteers were asked to consume 25 ml/d of raw EVOO for 12 weeks. The chemical composition of EVOO used in the study is described in Table 2\(^{29}\). Blood tests were performed at recruitment (T0) and after 12 weeks of EVOO consumption (T12). Plasma tyrosol and hydroxytyrosol levels were measured by HPLC, using the diode-array UV detection method as developed by Ruiz-Gutierrez et al.\(^{30}\), to evaluate compliance.

\textbf{Lipoprotein isolation}

Fasting human plasma was collected in heparin-containing tubes. Whole HDL and HDL\(_2\)/HDL\(_3\) subclasses were isolated.

\begin{table}[h]
\centering
\caption{Clinical and biochemical parameters of the participants at baseline and after 12 weeks of extra-virgin olive oil consumption (Mean values with their standard errors or standard deviations)}
\begin{tabular}{lcccc}
\hline
 & \multicolumn{2}{c}{T0} & \multicolumn{2}{c}{T12} \\
 & Mean & SEM & Mean & SEM \\
\hline
\textbf{n} & 26 & & 24.9 & 0.59 \\
\textbf{Women} & 18 & & 123 & 2.4 \\
\textbf{Men} & 8 & & 1.50 & 0.06 \\
\textbf{Age (years)} & 20.66 & 53.28 & 2.91 & 0.15 \\
\textbf{SD} & & & 1.59 & 0.04 \\
\textbf{BMI (kg/m\textsuperscript{2})} & 24.9 & 0.65 & 24.9 & 0.65 \\
\textbf{Systolic blood pressure (mmHg)} & 126 & 3.10 & 123 & 2.4 \\
\textbf{Diastolic blood pressure (mmHg)} & 77 & 1.66 & 77 & 1.66 \\
\textbf{TC (mmol/l)} & 5.10 & 0.16 & 4.94 & 0.019 \\
\textbf{TAG (mmol/l)} & 1.27 & 0.13 & 1.16 & 0.11 \\
\textbf{HDL-C (mmol/l)} & 1.50 & 0.07 & 1.50 & 0.07 \\
\textbf{LDL-C (mmol/l)} & 3.03 & 0.13 & 2.91 & 0.15 \\
\textbf{ApoA1 (g/l)} & 1.60 & 0.05 & 1.59 & 0.05 \\
\textbf{ApoB (g/l)} & 0.90 & 0.04 & 0.90 & 0.04 \\
\textbf{ApoB:ApoA1} & 0.80 & 0.04 & 0.84 & 0.04 \\
\textbf{TC:HDL-C} & 3.58 & 0.19 & 3.43* & 0.38 \\
\textbf{LDL-C:HDL-C} & 2.25 & 0.14 & 2.01 & 0.16 \\
\textbf{TAG:HDL-C} & 0.94 & 0.12 & 0.84* & 0.10 \\
\textbf{Glucose (mmol/l)} & 4.42 & 0.10 & 4.44 & 0.10 \\
\textbf{Insulin (pmol/l)} & 35.20 & 4.01 & 37.63 & 3.98 \\
\textbf{CRP (mg/l)} & 3.43 & 0.26 & 3.48 & 0.30 \\
\hline
\end{tabular}
\end{table}

\footnotesize{TC, total cholesterol; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; CRP, C-reactive protein. * Mean values were significantly different from those at T0 (P<0.05; Wilcoxon matched-pairs signed-rank test).}

---

\section*{References}

\begin{itemize}
\item\cite{1}
\item\cite{2}
\item\cite{3}
\item\cite{4}
\item\cite{5}
\item\cite{6}
\item\cite{7}
\item\cite{8}
\item\cite{9}
\item\cite{10}
\item\cite{11}
\item\cite{12}
\item\cite{13}
\item\cite{14}
\item\cite{15}
\item\cite{16}
\item\cite{17}
\item\cite{18}
\item\cite{19}
\item\cite{20}
\item\cite{21}
\item\cite{22}
\item\cite{23}
\item\cite{24}
\item\cite{25}
\item\cite{26}
\item\cite{27}
\item\cite{28}
\item\cite{29}
\item\cite{30}
\end{itemize}
within 2 and 4 h, respectively, using the method of Sattler et al.\(^{(33)}\). HDL were stored in phosphate buffer containing 10% sucrose at \(-80^\circ C\) until used. Before the analysis, frozen HDL were dialysed overnight at 4°C in 10 mM-sodium phosphate buffer (pH 7.0) to remove sucrose, and protein concentrations were measured using commercial assay kits (Bio-Rad) according to the manufacturer’s instructions.

### Cell cultures

Human THP-1 monocytes and J774 macrophages were grown in RPMI-1640 medium and DMEM, respectively. The media were supplemented with 10% heat-inactivated FBS, 50 mM-β-mercaptoethanol (only for THP-1), 2 mM-L-glutamine, 5 mg/ml of glucose and 100 U/ml of penicillin. THP-1 monocytes were differentiated into macrophages by cultivating the cells in the presence of 100 µg/ml of human apoA-I in order to measure CE.

Human monocyte isolation and differentiation into macrophages

Human monocytes were isolated as described previously\(^{(32)}\) and were differentiated into macrophages (human monocyte-derived macrophages (HMDM)). Briefly, peripheral blood mononuclear cells were isolated by density gradient centrifugation on Ficoll-Paque™ PLUS columns according to the manufacturer’s instructions (GE Healthcare). Peripheral blood mononuclear cells were resuspended in 10% FBS-RPMI medium, plated in twelve-well plates (0.5 x 10^5 cells per well) pre-coated with 20% autologous serum, and were allowed to attach for 20 min. Unattached cells were then removed from the medium. Attached monocytes were incubated with 10% FBS-RPMI containing 100 µg/ml of human apoA-I and 100 U/ml of penicillin–streptomycin.

### Cholesterol efflux measurements

THP-1, J774 and Fu5AH cells were incubated in fresh culture medium containing 0.2 µCi/ml of [³H]cholesterol for 24 h. The cells were then washed and incubated in serum-free medium containing 1% bovine serum albumin for 12 h for equilibration following which they were washed and suspended in fresh medium without HDL (control), fresh medium containing 5% serum, fresh medium containing 50 µg/ml of whole HDL, or fresh medium containing 50 µg/ml of HDL\(_{2}\) or HDL\(_{3}\) obtained from each volunteer.

In another series of experiments, J774 macrophages were incubated for 12 h with 0.3 mM-cyclic AMP to yield ABCA1-enriched macrophages. The cells were then washed and incubated with 5% serum, HDL\(_{2}\) or HDL\(_{3}\) for 24 h. ABCG1 overexpression on THP-1 macrophages was induced by incubating phorbol myristate acetate-pretreated THP-1 macrophages with 5 µM-22(β)-hydroxy-cholesterol for 24 h\(^{(33)}\). RT-PCR and Western blot analyses were performed to confirm the overexpression of ABCG1 mRNA and protein, respectively.

HMDM were loaded with [³H]cholesterol (1 µCi/ml) for 48 h. Labelled HMDM were washed and incubated in serum-free medium containing 1% bovine serum albumin for 12 h for equilibration following which they were incubated for 4 h with 25 µg/ml of human apoA-I in order to measure CE. CE was measured by liquid scintillation counting. The percentage of radiolabelled CE was calculated using the following formula:

\[
\% \text{ CE} = \left( \frac{\text{cpm in medium} - \text{cpm in cells}}{\text{cpm in medium}} \right) \times 100
\]

where cpm is counts per min.

### Agarose gel electrophoresis and Western blotting

HDL subclasses were analysed by agarose gel electrophoresis. Aliquots of plasma and HDL\(_{2}\) and HDL\(_{3}\) particles obtained from the volunteers at T0 and T12 were separated on 0.75% agarose gel electrophoresis and Western blotting. Immunocomplexes were visualised using an enhanced chemiluminescence Western blotting detection system followed by autoradiography.

### Table 2. Chemical composition of extra-virgin olive oil (EVOO) used in the study\(^{(29)}\)

<table>
<thead>
<tr>
<th>Fatty acids (%)</th>
<th>EVOO</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:0</td>
<td>10.4</td>
</tr>
<tr>
<td>18:0</td>
<td>2.76</td>
</tr>
<tr>
<td>18:1n-9</td>
<td>71.0</td>
</tr>
<tr>
<td>18:2n-6</td>
<td>12.9</td>
</tr>
<tr>
<td>18:3n-3</td>
<td>1.04</td>
</tr>
<tr>
<td>Sterols (mg/100 g oil)</td>
<td>319</td>
</tr>
<tr>
<td>Schottenol</td>
<td>0</td>
</tr>
<tr>
<td>Spinasterol</td>
<td>0</td>
</tr>
<tr>
<td>Stigmasta-8,22-dien-3β-ol</td>
<td>0</td>
</tr>
<tr>
<td>α-Sitosterol</td>
<td>156</td>
</tr>
<tr>
<td>Campesterol</td>
<td>12</td>
</tr>
<tr>
<td>Others</td>
<td>151</td>
</tr>
<tr>
<td>Tocopherols (mg/kg oil)</td>
<td>257</td>
</tr>
<tr>
<td>α</td>
<td>190</td>
</tr>
<tr>
<td>δ</td>
<td>42</td>
</tr>
<tr>
<td>γ</td>
<td>26</td>
</tr>
<tr>
<td>Phenolic compounds (µg/kg oil)</td>
<td>792,983</td>
</tr>
<tr>
<td>Vanillic acid</td>
<td>359</td>
</tr>
<tr>
<td>Syringic acid</td>
<td>0</td>
</tr>
<tr>
<td>Ferulic acid</td>
<td>51</td>
</tr>
<tr>
<td>Tyrosol</td>
<td>19,573</td>
</tr>
<tr>
<td>Others</td>
<td>773,000</td>
</tr>
</tbody>
</table>

O. Helal et al.
peroxidase secondary antibodies.

Western blotting analyses

To gain more insight into the effect of EVOO consumption on CE expression in HMDM were quantified by Western blot analysis at T0 and T12. Moreover, the expression of these proteins was also measured in J774 macrophages after incubation of these cells, for 12 h, with EVOO total phenolic extract or with the major phenolic compounds of EVOO such as tyrosol and hydroxytyrosol. Western blotting analyses were performed using as an enhanced chemiluminescence reagent(35).

HDL fluidity measurements

Lipoprotein fluidity was measured based on the steady-state anisotropy of 1,6-diphenyl-1,3,5-hexatriene (DPH) dissolved in tetrahydrofuran, as described previously(36). Briefly, HDL were incubated with 1 µM-DPH for 15 min at 37°C in the dark with constant stirring. Steady-state fluorosence polarisation of DPH was measured at 37°C using a Hitachi spectrofluorometer model F-4500 (Hitachi, Limited). DPH was excited using a vertically polarised light at 360 nm, and emission intensities were detected at 430 nm through a polariser orientated parallel and perpendicular to the direction of polarisation of the excitation beam. Steady-state fluorescence anisotropy (r) was calculated using the following equation from the FL solution program (Hitachi):

\[ I_v - GI_p / (I_v - 2GI_p) \]

where \( I_v \) and \( I_p \) are the parallel and perpendicular polarised fluorescence intensities, and \( G \) is the monochromator grating correction factor. Fluidity is the inverse value of anisotropy and is expressed as 1/r for steady-state fluorescence anisotropy.

Table 3. Sequences of primers for real-time quantitative PCR

<table>
<thead>
<tr>
<th>Genes</th>
<th>Forward primers (5’ to 3’)</th>
<th>Reverse primers (5’ to 3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABCA1</td>
<td>TCATCTTACATGGTCTTACAGC</td>
<td>GTGCTGGGAGATCTGAACAC</td>
</tr>
<tr>
<td>ABCG1</td>
<td>GCCGCTGGCTATCAAGCA</td>
<td>GATAGGGATCTCCTTCACATGGTGTG</td>
</tr>
<tr>
<td>SR-BI</td>
<td>TTCTTACATGGTCTTACCTC</td>
<td>GCCAGGATAGGCCTTACAG</td>
</tr>
<tr>
<td>β-Actin</td>
<td>GAAAGGTGAAGGTGACCA</td>
<td>TAAAGGAAGTGGTGG</td>
</tr>
</tbody>
</table>

ABCA1, ATP-binding cassette A1; ABCG1, ATP-binding cassette G1; SR-BI, scavenger receptor class B type I.

Results

Table 1 presents the clinical and biochemical parameters of the volunteers at baseline (T0) and after 12 weeks of EVOO consumption (T12). The volunteers (mean age 53±28 (SEM 20.66) years) were healthy and non-obese (BMI 24.9 (SEM 0.65) kg/m²) with lipid profiles and systolic and diastolic blood pressure in normal ranges. There were no significant differences in serum TAG, total cholesterol, LDL-cholesterol, and other cardiovascular risk markers between T0 and T12. The TAG: HDL and total cholesterol:HDL ratios, which are atherogenic indices, decreased respectively by 10.1% (P<0.05) and 4.2% (P<0.05) at T12. Plasma tyrosol and hydroxytyrosol contents showed a small (not statistically significant) increasing trend after 12 weeks of EVOO consumption (results not shown).

Effect of extra-virgin olive oil consumption on serum-mediated cholesterol efflux

CE is the first rate-limiting step of RCT and is influenced by the capacity of HDL to act as a cholesterol acceptor and of peripheral cells to release excess cholesterol.

We first investigated the effect of 12 weeks of EVOO consumption on the capacity of serum to mediate CE. As shown in Fig. 1(a), 12 weeks of EVOO consumption resulted in a
9.8% \( (P<0.01) \) increase in the capacity of serum to mediate CE from THP-1 macrophages.

We then investigated which CE pathway was stimulated the most after 12 weeks of EVOO consumption. We used J774 macrophages to investigate the involvement of ABCA1. J774 macrophages have a low basal expression of ABCA1, which is overexpressed following a pretreatment with cyclic AMP\(^8\). It was found that 12 weeks of EVOO consumption increased the capacity of serum to mediate CE from ABCA1-enriched J774 macrophages by 18.85% \( (P<0.001) \) while no effect was observed with ABCA1-non-enriched macrophages (Fig. 1(b)).

We used Fu5AH cells to investigate the involvement of the SR-BI pathway in this process. Fu5AH cells express high levels of SR-BI and lack functional ABCA1\(^5\). We found that 12 weeks of EVOO consumption enhanced the capacity of serum to mediate CE from Fu5AH cells via the SR-BI pathway by 14.81% \( (P<0.001; \) Fig. 1(c)).

**Effect of extra-virgin olive oil consumption on HDL-mediated cholesterol efflux**

In light of the results obtained with serum and to better understand the beneficial effect of EVOO on cholesterol homeostasis, we investigated the effect of 12 weeks of EVOO consumption on the capacity of HDL to mediate CE using THP-1 macrophages and Fu5AH cells incubated with whole HDL. We did not use ABCA1-enriched J774 cells because they do not interact with whole HDL or with the HDL2 subfraction\(^7,37–39\). Fig. 2(a) shows that 12 weeks of EVOO consumption enhanced the capacity of whole HDL to mediate CE from THP-1 macrophages by 11.93% \( (P<0.01) \).

We then pretreated THP-1 macrophages with 22(R)-hydroxy-cholesterol for 24 h to induce overexpression of ABCG1\(^{33}\). mRNA and protein expression measurements confirmed that ABCG1 was up-regulated in THP-1 macrophages (results not shown). While the up-regulation of ABCG1 increased HDL-mediated CE at T0, the increase was significantly higher at T12 \( (24.57 \text{ (SEM 4.89)} \text{ % at T12 } v. \text{ 11.77 (SEM 4.33)} \text{ % at T0; Fig. 2(b))} \).

The effect of 12 weeks of EVOO consumption on the capacity of HDL to mediate CE via the SR-BI pathway was also investigated. Fu5AH cells were used as a cholesterol acceptor. As shown in Fig. 2(c), the capacity of HDL to mediate CE was 16.4% higher at T12 than at T0 \( (P<0.05) \).

To determine which HDL subclass was involved in the increase in CE, HDL2 and HDL3 isolated from the volunteers at baseline (T0) and after 12 weeks of EVOO consumption (T12) were incubated separately with \(^[3]H\)cholesterol-loaded Fu5AH cells. HDL2-mediated CE from Fu5AH cells was 24.1% \( (P<0.05) \) higher at T12 than at T0, while HDL3 had no effect (Fig. 3(a)). In contrast, HDL4-mediated CE from ABCA1-enriched J774 macrophages was 15.2% \( (P<0.05) \) higher than from control J774 macrophages (Fig. 3(b)).

The percentage increase in HDL-mediated CE at T12 was comparable to that observed when 5% serum was used as the cholesterol acceptor.

**Effect of extra-virgin olive oil consumption on the distribution of HDL subclasses and their biophysical properties**

We investigated whether the increase in CE through the ABCA1/ABCG1 and SR-BI pathways induced by EVOO...
consumption might be related to a difference in HDL distribution, particularly the levels of pre-β-HDL₃ and α-HDL₃ levels. We found that 12 weeks of EVOO consumption did not induce a significant change in either pre-β-HDL or α-HDL levels (results not shown). We also assessed the distribution of all HDL particles (small v, intermediate v, large HDL) in an attempt to explain the increase in the capacity of HDL to mediate CE through the ABCG1 and SR-BI pathways. No significant changes were observed between T₀ and T₁₂ in the distribution of HDL particles (Table 4).

In addition to the interactions with the ABCA1 transporter and SR-BI receptor, the capacity of HDL to mediate CE also depends on their physico-chemical properties (27), including an increase in the fluidity of the phospholipidic layer of HDL that, in turn, increases the capacity of HDL to mediate CE. Fluidity is an indirect measure of the fatty acid composition of HDL and is determined by anisotropy fluorescence measurements. Due to its high MUFA content, olive oil can induce physico-chemical changes in the lipid composition of HDL and thus in their biophysical structure. The results confirmed that 12 weeks of EVOO consumption increased the fluidity of the phospholipidic layer of HDL by 13% (P<0.001) as measured by fluorescence anisotropy (Fig. 4).
revealed that 12 weeks of EVOO consumption increased the
fluidity of the phospholipidic layer of HDL was measured at baseline (T0) and after 12 weeks of EVOO consumption (T12). Fluidity is the inverse of the value of anisotropy and is expressed as 1/

**Effect of extra-virgin olive oil consumption on the capacity of human monocyte-derived macrophages to release excess cholesterol**

In the second part of the present study, we investigated the effect of EVOO consumption on the capacity of HDMD to release excess cholesterol, which is the second-limiting step in the RCT process. We used standard human apoA-I as the cholesterol acceptor. Monocytes were isolated from each volunteer at T0 and T12 and were transformed into macrophages (HMDM) as described in the Materials and methods section. HMDM were loaded with [3H]cholesterol and were then incubated with 25 μg/ml of apoA-I to measure CE. The results revealed that 12 weeks of EVOO consumption increased the capacity of HMDM to transfer excess cholesterol to apoA-I by over 44% (**P** < 0.001; Fig. 5).

In an attempt to explain the increase in cholesterol release from HMDM following EVOO consumption, we measured ABCA1, ABCG1 and SR-BI mRNA and protein expression in HMDM obtained from the volunteers at T0 and T12. As a result, we found that 12 weeks of EVOO consumption increased **ABCA1** and **ABCG1** mRNA expression by 27.51% (**P** < 0.0001) and 26.48% (**P** < 0.001), respectively (Fig. 6(a) and (b)). Interestingly, **SR-BI** mRNA expression was reduced by approximately 30% (**P** < 0.0001; Fig. 6(c)). These results were confirmed by the protein expression measurements, which showed that there was a significant increase in **ABCA1** (68.08%, **P** < 0.001) and **ABCG1** (35.79%, **P** < 0.01) protein expression and a decrease in **SR-BI** protein expression (−2.51%, **P** < 0.05) following 12 weeks of EVOO consumption (Fig. 6(d) and (e)).

To confirm the effect of EVOO consumption on cholesterol transporter protein levels, especially **ABCA1** and **ABCG1** in HMDM, we first incubated EVOO polyphenol extracts (0–320 μg/ml) with J774 macrophages and measured ABCA1 protein expression. Overnight incubation of J774 macrophages with EVOO polyphenol extracts significantly increased ABCA1 protein expression in a dose-dependent manner (Fig. 7(a)) as measured by Western blot analysis. In light of these results, we then investigated the effect of purified thyr-sol and hydroxythyrlosol (two major EVOO polyphenols) on **ABCA1**, **ABCG1** and **SR-BI** protein expression in J774 macrophages. The results (Fig. 7) showed a significant

![Fig. 4.](https://www.cambridge.org/core/https://www.cambridge.org/core/https://www.cambridge.org/core/terms)

![Fig. 5.](https://www.cambridge.org/core/https://www.cambridge.org/core/https://www.cambridge.org/core/terms)
increase in ABCA1 and ABCG1 protein expression in the presence of both tyrosol and hydroxytyrosol (5 and 10 μM; Fig. 7(b), (c), (e) and (f)), whereas no significant effect was observed with respect to SR-BI expression (Fig. 7(d) and (g)).

Discussion

Olive oil is the main source of fat in the Mediterranean diet. A large body of evidence shows that the Mediterranean diet, which is high in olive oil, is associated with a lower incidence of CHD\(^{40-43}\). The beneficial effect of olive oil consumption is related to its high MUFA and phenol content, which have antioxidant and anti-inflammatory properties\(^{19,44-47}\). A diet rich in olive oil induces a change in lipid metabolism\(^{48}\) and an increase in the resistance of LDL to lipid peroxidation\(^{49}\).

Covas et al.\(^{19}\) showed that consuming EVOO increases the level of phenolic compounds in the serum and LDL, which may explain its protective effect against free radical-induced lipid peroxidation. However, no studies have investigated the effect of olive oil consumption by human subjects on the principal anti-atherogenic activity of HDL, which is their capacity to regulate or maintain cholesterol homeostasis.

HDL maintain cholesterol homeostasis by their role in RCT, facilitating the efflux of cholesterol from peripheral tissues and transporting it back to the liver to be eliminated in the bile and faeces\(^{3}\). This process involves the interaction of lipid-poor

---

**Fig. 6.** Extra-virgin olive oil (EVOO) increases ATP-binding cassette (ABC) A1 and ABCG1 mRNA and protein expression in human monocyte-derived macrophages (HMDM). Human monocytes were cultured and differentiated into macrophages in phorbol myristate acetate-Roswell Park Memorial Institute medium in the presence of autologous sera to induce differentiation into macrophages (HMDM). HMDM were lysed and their (a) ABCA1, (b) ABCG1 and (c) scavenger receptor class B type I (SR-BI) mRNA content was quantified by quantitative PCR (qPCR). The comparative threshold cycle (C) method was used to quantify the transcript levels and to normalise β-actin expression. Western blotting was used to evaluate (d) ABCA1, ABCG1 and SR-BI protein levels in HMDM. (e) Protein bands were quantified by densitometry. The qPCR and Western blotting analyses were carried out at baseline (T0) and after 12 weeks of EVOO consumption (T12). For each subject, measurements were done in triplicate. A Wilcoxon matched-pairs signed-rank test was used to compare differences between groups. Values are means, with their standard errors represented by vertical bars. Mean values were significantly different from those at T0: * \(P<0.05\), ** \(P<0.01\), *** \(P<0.001\).
The plasma membrane of cholesterol transporters, principally ABCA1 and ABCG1 (53). The goals of the present study were to investigate, in healthy volunteers, the effect of 12 weeks of extra-virgin olive oil (EVOO) consumption on the capacity of HDL to mediate cholesterol efflux (CE). Extracellular cholesteryl esters (CE) are formed following lipidation of apoA-I by ABCA1. The increase in phospholipidic layer fluidity is an indirect measure of a change in HDL lipid composition and confirmed that a change in the biochemical composition of HDL following the consumption of EVOO may, in part, contribute to the increase in their capacity to mediate CE. On the other hand, it is well known that the oxidation of HDL significantly affects their capacity to promote CE (35,56) and that dietary antioxidants increase the resistance of these lipoproteins to lipid peroxidation (47).

While Sola et al. (57) reported that virgin olive oil enrichment increases apoA-I concentrations in high-cardiovascular risk subjects. The present results indicated that EVOO consumption does not affect these parameters in healthy patients. Violante et al. (58) also reported that 3 months of EVOO consumption by hypercholesterolaemic subjects increased serum apoA-I concentrations by about 9%. However, given the conditions used in the present study, it was not surprising that there was no increase in apoA-I levels after 3 months of EVOO supplementation. On the one hand, all of our volunteers were healthy with no cardiovascular risk factors and, on the other hand, the apoA-I levels and lipid profiles of our volunteers were in normal ranges. In the present study, EVOO had no effect on circulating HDL levels or HDL subclass distribution, but did improve the capacity of HDL to mediate CE, clearly suggesting that EVOO consumption improves HDL functionality, which is more important than HDL concentrations in determining their atheroprotective capacity.

The use of J774, THP-1 and Fu5AH cells allowed us to determine that EVOO consumption stimulates CE mediated by both pre-β-HDL and the mature fractions of HDL (HDL₂ and HDL₃). Pre-β-HDL are considered important extracellular acceptors of effluxed peripheral tissue cholesterol. They are formed following lipidation of apoA-I by ABCA1. The ABCA1 transporter mediates CE in a unidirectional manner to apoA-I and pre-β-HDL. Western blotting and PAGE analyses did not reveal any significant changes in pre-β-HDL levels or in HDL subclass distribution between T0 and T12. Previous studies, including the present study, showed that oxidative modifications to apoA-I affect its capacity to interact with ABCA1 transporters and to mediate CE (35,57). While EVOO consumption did not have an effect on apoA-I levels that could explain the increased CE, it should be noted that olive oil contains several components (α-tocopherol, β-carotene, sterols, terpene, squalene and phenolic compounds (19,41,59)) with antioxidant activity that may protect apoA-I against oxidative damage, thus contributing to stronger apoA-I and pre-β-HDL/ABCA1 interactions that mediate CE.
The efflux of cholesterol via ABCG1 and SR-BI is mediated by mature HDL, while oxidative damage to apoA-I and whole HDL particles is reduced by polyphenolic compounds, thus increasing CE. The increase in CE mediated by mature HDL also depends on their biochemical and physico-chemical properties, and the increase in the phospholipidic fluidity of HDL may in part explain the improvement in the capacity of HDL to mediate CE.

EVOO consumption increased the capacity of HMDM to release excess cholesterol to apoA-I by 44% ($P_{<0.001}$), which is comparable to the 42% increase in CE obtained by Rosenblat et al.\(^\text{(58)}\) with mouse peritoneal macrophages after 8 weeks of EVOO consumption. CE proteins on HMDM plasma membranes, especially ABCA1 and ABCG1 transporter proteins, were significantly up-regulated following EVOO consumption, as measured by mRNA and protein expression. The increase in protein expression may explain the significant increase in cholesteryl release from HMDM. A recent study on healthy human subjects showed that consuming coffee, which has a high phenolic acid content, enhances HDL-mediated CE by increasing ABCG1 and SR-BI expression\(^\text{(60)}\). While we cannot explain this discrepancy, it is surprising that polyphenols induced an increase in ABCG1 expression but had no effect on ABCA1 given that both proteins are regulated by the liver X receptor-$\alpha$, which is activated by phenolic acids\(^\text{(61)}\), and that, in the present study, phenolic compounds purified from EVOO up-regulated both ABCA1 and ABCG1 transporters in J774 macrophages.

In contrast, SR-BI mRNA and protein expression was significantly down-regulated after 12 weeks of EVOO consumption. While we have not investigated the factors that may explain this down-regulation, Miles et al.\(^\text{(62)}\) showed that 12 weeks of olive oil consumption by mice caused a reduction in SR-BI protein expression. They interpreted this reduction as a beneficial effect of olive oil consumption in that it prevented the formation of foam cells, which they attributed to unsaturated fatty acids in the olive oil\(^\text{(62)}\). Wang et al.\(^\text{(53)}\) also showed that the SR-BI receptor does not promote macrophage RCT in vivo and that RCT occurs principally via ABCA1 and ABCG1 transporters. We did not observe a significant change in SR-BI protein expression following 24h incubation with purified polyphenols.

It is noteworthy that, in addition to its beneficial effect on the capacity of serum and HDL to mediate CE, 12 weeks of EVOO consumption significantly reduced the total cholesterol:HDL and TAG:HDL ratios. These results are in agreement with those of Violante et al.\(^\text{(58)}\) and showed that EVOO consumption has a beneficial effect on other atherosclerosis markers.

In conclusion, the present results showed that 12 weeks of EVOO consumption significantly increased the capacity of HDL to mediate CE and of HMDM to release excess cholesterol. The increase in the capacity of HDL to mediate CE was independent of HDL concentraction and was probably due to improvements in HDL functionality. The increase in the capacity of HMDM to release excess cholesterol can be explained by the increase in ABCA1 and ABCG1 mRNA and protein expression by these cells. The capacity of HDL to mediate CE and of macrophages to release excess cholesterol are two components of RCT, which suggests that EVOO could have a significant effect on the modulation, in vivo, of cholesterol homeostasis and significantly reduce cholesterol deposits in the arteries. Nevertheless, the present study presents some limitations: (1) the design of the study lacks a control group; (2) the diet of the participants was not controlled. Indeed, dietary changes, besides EVOO consumption, could promote an increase in HDL functionality (i.e. other polyphenols or antioxidants); (3) physical activity, which is another possible confounder variable that was not registered; and (4) the age of the participants was in the range of middle-aged/mature people, which limits the extrapolation of the obtained results to a young population. Therefore, due to these limitations, the present study should be considered as a pilot study. However, further studies, considering these limitations, are needed to investigate the effect of EVOO consumption on RCT.

**Acknowledgements**

This study was supported by a grant from the Canadian Institutes of Health Research (MOP-88912). The authors’ contributions were as follows: A. K. designed the study and obtained funds from the Canadian Institutes of Health Research; O. H. carried out the experiments about the in vivo effect of olive oil; H. B. carried out the experiments on the in vivo effect of EVOO extracts; S. L. participated in the sample collections and the preparation of lipoproteins; O. H. and H. B drafted the manuscript; A. K. revised the manuscript and completed the discussion. All authors read and approved the final manuscript. The authors declare that there are no conflicts of interest.

**References**


